The study is expected to be initiated in Q4 2022 and will be conducted by the Company's partner,
Contact:
Tel: +44 (0) 191 511 8500
Email: info@shieldtx.com
(C) 2022 Electronic News Publishing, source
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.75 GBX | -5.41% | +14.75% | -73.88% |
05-10 | Shield Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
04-30 | EARNINGS AND TRADING: Software Circle & Beximco report higher revenue | AN |
The study is expected to be initiated in Q4 2022 and will be conducted by the Company's partner,
Contact:
Tel: +44 (0) 191 511 8500
Email: info@shieldtx.com
(C) 2022 Electronic News Publishing, source
1st Jan change | Capi. | |
---|---|---|
-73.88% | 18.33M | |
+9.42% | 114B | |
+11.84% | 104B | |
-14.15% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.16% | 17.89B | |
+7.99% | 14.28B | |
+36.24% | 12.55B |